POVIDONE-IODINE BETADINE
|
|
- Donald Campbell
- 5 years ago
- Views:
Transcription
1 POVIDONE-IODINE BETADINE NAME OF PRODUCT BETADINE 10% OINTMENT Read this leaflet carefully before you start using BETADINE ointment. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. If any of the side effects become serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. DESCRIPTION OF PRODUCT POVIDONE-IODINE (BETADINE ) ointment is a reddish brown, smooth, homogenous ointment. It is available in 5 & 15 g aluminum tube. 1. WHAT IS BETADINE OINTMENT? POVIDONE-IODINE (BETADINE ) ointment is a topical agent active against organisms commonly encountered in skin and wound infections. It contains 10% povidone-iodine equivalent to 1% available iodine. The active ingredient povidone-iodine substantially retains the broad spectrum germicidal activity of iodine against the commonly encountered organisms in skin and wound infections, without the undesirable features or disadvantages of iodine. POVIDONE-IODINE (BETADINE ) ointment is decisively microbicidal against all 4 major classes of pathogens: bacteria (both Gram-positive and Gram-negative, as well as antibiotic-resistant strains) fungi, viruses and protozoa. The foremost documented broad spectrum topical microbicidal power of POVIDONE-IODINE (BETADINE ) ointment is active even in the presence of blood, pus and serum and the germicidal activity is more prolonged than that of iodine tincture. POVIDONE-IODINE (BETADINE ) ointment is in a water-soluble base and is not greasy or sticky. It permits bandaging of treated area, is virtually non-irritating to skin and mucosa and does not block air from reaching site of application. It easily washes off from skin and natural fabrics. POVIDONE-IODINE (BETADINE ) ointment does not interfere with granulation or skin grafting in burns. 2. STRENGTH OF BETADINE OINTMENT Each g contains 100 mg POVIDONE-IODINE (BETADINE ) equivalent to 10 mg available iodine 3. WHAT IS BETADINE OINTMENT USED FOR? POVIDONE-IODINE (BETADINE ) ointment is an ideal topical agent for the treatment of common skin infections; prevention of infection in minor burns, lacerations, cuts and abrasions; and for infection control during insertion and care of urinary catheters, circumcision, suture removal and dressing changes.
2 POVIDONE-IODINE (BETADINE ) ointment may be used for degerming care of stasis ulcers, decubitus ulcers and the umbilical area. It can be used also for degerming during use of intravenous devices in blood transfusions, hyperalimentation, cutdowns, CVP catheterization and in other procedures where degerming is needed. 4. HOW MUCH AND HOW OFTEN SHOULD YOU USE BETADINE OINTMENT? Use POVIDONE-IODINE (BETADINE ) Ointment as prescribed by your doctor. Clean and dry the affected skin. Apply POVIDONE-IODINE (BETADINE ) ointment liberally and cover with a dressing or bandage. POVIDONE-IODINE (BETADINE ) ointment may be used as often as required. If you have any further questions on the use of POVIDONE-IODINE (BETADINE ) ointment, ask your doctor or pharmacist. 5. WHEN SHOULD YOU NOT USE BETADINE OINTMENT? POVIDONE-IODINE (BETADINE ) ointment should not be used: If you are allergic to iodine or povidone If you have an overactive thyroid gland (hyperthyroidism) or any thyroid diseases If you are on lithium therapy Before and after a specific medical treatment involving the use of radioactive iodine If you feel you have experienced an allergic reaction, stop using POVIDONE-IODINE (BETADINE ) ointment and inform your doctor or pharmacist immediately. 6. SIDE EFFECTS All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical attention if you get some of the side effects. The side effects listed below may not include all of the side effects reported. For more information about any other possible risks associated with POVIDONE-IODINE (BETADINE ) ointment, please consult your doctor or pharmacist. Please note that the side effects related to the use of POVIDONE-IODINE (BETADINE ) ointment occur rarely. Rarely, hypersensitive/allergic skin reaction may occur, which can appear in the form of: itchiness redness small blisters Very rarely, acute generalized allergic reactions have been reported with drop in blood pressure difficulty in breathing swelling of the skin and mucosa
3 If you notice any side effects, please consult your doctor or pharmacist. The long term use of the product, not in accordance with the usage instructions mentioned under section 4, may lead to possible absorption of iodine into the body. This may lead to overactive thyroid gland function if you have a history of thyroid problems, rapid heartbeat (tachycardia) and restlessness imbalance of electrolytes abnormal blood concentration (osmolarity) abnormal kidney function (renal impairment) 7. WHAT OTHER MEDICINE OR FOOD SHOULD BE AVOIDED WHILE USING BETADINE OINTMENT? Do not apply other medications to the same affected areas you treat with POVIDONE- IODINE (BETADINE ) ointment, unless your doctor has told you so. It is not likely that other drugs you take orally or inject will have an effect on externally applied POVIDONE-IODINE (BETADINE ) ointment. The concomitant use of other externally applied wound healing medicines /preparations may alter the effect of POVIDONE-IODINE (BETADINE ) ointment or both. Products containing enzymatic component, alkali, mercury, silver, hydrogen peroxide, tannic acid and taurolidine may interact with povidone-iodine and should not be used concomitantly. Povidone-iodine products when used concomitantly or immediately after application of octenidine containing antiseptics in the same or adjacent sites may lead to transient dark discolorations in the areas involved. Due to the oxidative effect of povidone-iodine preparations various diagnostic agents can show false-positive lab results (e.g., tests with toluidine or gum guaiac for the determination of hemoglobin or glucose in the stool or the urine). Absorption of iodine from povidone-iodine may interfere with thyroid function tests. Do not start a new treatment medication without telling your doctor. For more information about any other possible risks associated with POVIDONE-IODINE (BETADINE ) ointment, please consult your doctor or pharmacist. 8. WHAT SHOULD YOU DO IF YOU MISS A DOSE? Follow the usage instructions mentioned in section 4. If you miss a treatment use it as soon as you remember. For more information please consult your doctor or pharmacist. 9. HOW SHOULD YOU KEEP BETADINE OINTMENT? Do not use POVIDONE-IODINE (BETADINE ) ointment after the expiry date indicated on the tube and carton. Store at temperatures not exceeding 30 C. 10. SIGNS & SYMPTOMS OF OVERDOSE In the unlikely event you experience any of the following symptoms: stomach pain, unable to pass urine, loss of appetite, weakness, nausea and vomiting, coughing up
4 blood, excessive sweating, difficulty in breathing, metabolic acidosis, anxiety and pale skin, immediately consult your doctor. Treatment is symptomatic and supportive. 11. WHAT TO DO WHEN YOU HAVE USED MORE THAN THE RECOMMENDED DOSAGE? Please consult your doctor or pharmacist. 12. CARE THAT SHOULD BE TAKEN WHEN USING BETADINE OINTMENT In pre-operative preparation, avoid pooling beneath the patient. Prolonged exposure to wet solution may cause irritation or rarely, severe skin reactions. Chemical burns of skin due to pooling may occur. In instances of skin irritation, contact dermatitis or hypersensitivity, discontinue use. Do not heat POVIDONE-IODINE (BETADINE ) ointment prior to use. Avoid getting POVIDONE-IODINE (BETADINE ) ointment in your eyes. Avoid solutions containing a detergent if treating open wounds with povidone-iodine. POVIDONE-IODINE (BETADINE ) ointment is intended FOR EXTERNAL USE ONLY. Not for use on extensive body areas and should not be used over a long period of time unless strictly indicated. Patients with goiter, thyroid nodules or other non-acute thyroid diseases are at risk of developing thyroid hyperfunction (hyperthyroidism) from the administration of large amounts of iodine. In this patient population, povidone-iodine should not be applied for an extended period of time and to large areas of the skin unless strictly indicated. Even after the end of the treatment one should look for the early symptoms of possible hyperthyroidism and if necessary the thyroid function should be monitored. It should not be used prior to or after radioiodine scintigraphy or radioiodine treatment of thyroid carcinoma. Newborns and small infants are at increased risk of developing hypothyroidism from the administration of large amounts of iodine. Because of the permeable nature of the skin and their increased sensitivity to iodine, the use of povidone-iodine should be kept to the absolute minimum in newborns and small infants. A check of their thyroid function (e.g. T 4 levels and TSH levels) may be necessary. Avoid use in patients with renal impairment. If symptoms persist, consult your doctor. Pregnancy and Lactation During pregnancy and lactation, POVIDONE-IODINE (BETADINE ) ointment should only be used if strictly prescribed by the doctor and its use should be kept to the absolute minimum. Seek medical advice from your doctor or pharmacist. 13. WHEN SHOULD YOU CONSULT YOUR DOCTOR? In case of allergic symptoms, stop treatment and consult your doctor.
5 Call your doctor if your symptoms do not improve or if they get worse. Also call your doctor if your symptoms had cleared up but reappeared again. Manufactured for: By: Mundipharma Distribution GmbH Interphil Laboratories, Inc. (Philippine Branch) Canlubang Industrial Estate, 29/F Robinsons Equitable Tower, Bo. Pittland, Cabuyao, Laguna #4 ADB Ave. cor. Poveda St., Ortigas Center, Pasig City, Philippines 1605 Under license by: Mundipharma B.V. / The Netherlands : BETADINE is a Registered Trademark. This leaflet was last revised on December 10, 2015 (CCDS v.4 16 November 2015). PH-BET-0566-V3-1215
PACKAGE LEAFLET: INFORMATION FOR THE USER ToboDexin 3 mg/g+1 mg/g eye ointment Tobramycin + Dexamethasone
PACKAGE LEAFLET: INFORMATION FOR THE USER ToboDexin 3 mg/g+1 mg/g eye ointment Tobramycin + Dexamethasone Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet. You
More informationPATIENT INFORMATION LEAFLET. Naseptin Nasal Cream chlorhexidine dihydrochloride and neomycin sulfate
PATIENT INFORMATION LEAFLET Naseptin Nasal Cream chlorhexidine dihydrochloride and neomycin sulfate Read all of this leaflet carefully before you start using this medicine Keep this leaflet. You may need
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER Fucidin 250 mg/5 ml Oral Suspension fusidic acid Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPHENYLEPHRINE. Please read this leaflet and the label of the medicine you purchased, carefully before you start using Phenylephrine.
What is in this leaflet PHENYLEPHRINE New Zealand Consumer Medicine Information The medicine you have purchased contains Phenylephrine. This leaflet is intended to provide information on the active ingredient
More informationPATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET PROSTATIN (OCTREOTIDE ACETATE INJECTION 10mcg, 50mcg) Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again.
More informationPATIENT INFORMATION LEAFLET
PPM Code: E1981 PATIENT INFORMATION LEAFLET SCHEDULING STATUS: S2 PROPRIETARY NAME DOSAGE FORM: film coated tablets Read all of this leaflet carefully because it contains important information for you.
More informationFASTUM 2.5% gel PACKAGE LEAFLET: INFORMATION FOR THE USER. What is in this leaflet? 1. WHAT FASTUM GEL IS AND WHAT IT IS USED FOR
PACKAGE LEAFLET: INFORMATION FOR THE USER FASTUM 2.5% gel KETOPROFEN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines the
More informationAUGMENTIN is also used to prevent infection from major surgery.
Injection Potassium clavulanate/amoxicillin sodium equivalent to 100 mg clavulanic acid/500 mg amoxicillin Potassium clavulanate/amoxicillin sodium equivalent to 200 mg clavulanic acid/1 g amoxicillin
More informationConsumer Medicine Information TOPICIL. Please read this leaflet carefully before you start using Topicil Capsules.
Clindamycin hydrochloride Capsules 150 mg What is in this leaflet Consumer Medicine Information TOPICIL Please read this leaflet carefully before you start using Topicil Capsules. This leaflet answers
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER Fucidin 250 mg Tablets sodium fusidate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
More informationPackage leaflet: Information for the user. Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime
Package leaflet: Information for the user Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationBicillin L-A Benzathine benzylpenicillin tetrahydrate
Bicillin L-A Benzathine benzylpenicillin tetrahydrate Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Bicillin L- A. It does not contain all the available
More informationPATIENT INFORMATION LEAFLET. Nasoxyl nasal spray solution 1 mg/ml
PATIENT INFORMATION LEAFLET Nasoxyl nasal spray solution 1 mg/ml Read all of this leaflet carefully, because it contains important information for you. This medicine is available without prescription.
More informationDexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop.
Dexamethasone Other Names: Decadron About This Drug Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop. Possible Side Effects (More Common) Increased
More informationPHOLCODINE. Please follow the instructions on the packaging of the medicine you purchased and in this leaflet before you start using pholcodine.
PHOLCODINE New Zealand Consumer Medicine Information What is in this leaflet The medicine you have purchased contains pholcodine. This leaflet is intended to provide information on the active ingredient
More informationHow Entecavir GH Works
entecavir monohydrate tablets ENTECAVIR GH Tablets Consumer Medicine Information What is in this leaflet Read this leaflet carefully before taking. This leaflet answers some common questions about. It
More informationPackage leaflet: Information for the patient. Megalac Almasilate 1 g/10 ml suspension. Active substance: almasilate
Package leaflet: Information for the patient Megalac Almasilate 1 g/10 ml suspension Active substance: almasilate Read all of this leaflet carefully before you start taking this medicine because it contains
More informationPATIENT INFORMATION LEAFLET CARZIN XL
SCHEDULING STATUS: S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: 4 mg film coated tablets. Read all of this leaflet carefully before you start taking. Keep this leaflet. You may need to read it
More informationIf you have any concerns about taking this medicine, ask your doctor or pharmacist.
CHAMPIX Varenicline tartrate What is in this leaflet This leaflet answers some common questions about CHAMPIX. It does not contain all the available information. It does not take the place of talking to
More informationRABEPRAZOL 10mg and 20mg Gastro-resistant Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets RABEPRAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet
More informationPATIENT INFORMATION LEAFLET PEPLOC RANGE
Scheduling Status: S4 Proprietary name, Strength and Pharmaceutical Form: Peploc 20 mg tablets Peploc 40 mg tablets Read all of this leaflet carefully before using PEPLOC 20 mg or 40 mg Keep this leaflet.
More informationDIXARIT 25 mcg Tablets Clonidine Hydrochloride
New Zealand Consumer Medicine Information DIXARIT 25 mcg Tablets Clonidine Hydrochloride What is in this leaflet This leaflet answers some common questions about DIXARIT tablets. It does not contain all
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. SALAGEN 5 mg film-coated tablets. Pilocarpine hydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE USER SALAGEN 5 mg film-coated tablets Pilocarpine hydrochloride Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may
More informationDulcolax Tablets and Dulcolax Suppositories Bisacodyl
Consumer Medicine Information Tablets and Suppositories Bisacodyl What is in this leaflet 1. What is used for 2. Before you use a) When you must not use b) Before you start to use c) Pregnancy d) Breastfeeding
More informationPackage leaflet: Information for the patient UNITED KINGDOM Feldene 5mg/g Gel piroxicam
Package leaflet: Information for the patient UNITED KINGDOM Feldene 5mg/g Gel piroxicam Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationSPASMEX FORTE 5mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER SPASMEX FORTE 5mg tablets TROSPIUM This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationCeclor CD cefaclor monohydrate sustained release tablets
Ceclor CD cefaclor monohydrate sustained release tablets Consumer Medicine Information (CMI) What is in this leaflet This leaflet answers some common questions about Ceclor CD. It does not contain all
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION BAVENCIO (buh-ven-see-oh) Avelumab for Injection Solution for Intravenous Infusion Read this carefully before you start
More informationSUCRALFATE ISELPIN 1 g Tablet
1.0 PHARMACOLOGIC CATEGORY CYTOPROTECTOR 2.0 DESCRIPTION SUCRALFATE ISELPIN 1 g Tablet Sucralfate is a white, amorphous powder which is soluble in strong acids and in alkalis but practically insoluble
More informationPATIENT INFORMATION LEAFLET. Nu-Seals 75 aspirin (acetylsalicylic acid)
PATIENT INFORMATION LEAFLET Nu-Seals 75 aspirin (acetylsalicylic acid) Read all of this leaflet carefully before you start taking this medicine Keep this leaflet. You may need to read it again. If you
More information1.3.1 PACKAGE LEAFLET: INFORMATION FOR THE USER
Fusidic acid 20 mg/g cream Page 1 of 6 1.3.1 PACKAGE LEAFLET: INFORMATION FOR THE USER AffusineAffusine 20 mg/g cream Fusidic Acid Read all of this leaflet carefully before you start using this medicine
More informationNEXIUM INTRAVENOUS esomeprazole sodium
NEXIUM INTRAVENOUS esomeprazole sodium Consumer Medicine Information What is in this leaflet This leaflet answers some of the common questions people ask about NEXIUM Intravenous (IV). It does not contain
More informationBISOLVON Chesty Forte.
New Zealand Consumer Medicine Information BISOLVON Chesty Forte Tablets 8 mg Bromhexine hydrochloride What is in this leaflet This leaflet answers some common questions about BISOLVON Chesty Forte. It
More informationPemetrexed APOTEX Powder for Injection Contains the active ingredient pemetrexed (as disodium)
Pemetrexed APOTEX Powder for Injection Contains the active ingredient pemetrexed (as disodium) Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet
More informationIt does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.
Serc betahistine dihydrochloride Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Serc. It does not contain all the available information. It does
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. DF118 Tablets 30mg (Dihydrocodeine Hydrogen Tartrate)
PACKAGE LEAFLET: INFORMATION FOR THE USER DF118 Tablets 30mg (Dihydrocodeine Hydrogen Tartrate) Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need
More informationPATIENT INFORMATION LEAFLET
FERIFER-40 Oral Solution, 40 mg/5 ml For oral use. PATIENT INFORMATION LEAFLET Active substance(s): Each one spoon solution (5 ml) contains 40 mg of iron (as iron III polymaltose complex). Excipient(s):
More informationFLUIMUKAN PLUS 600 mg effervescent tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER FLUIMUKAN PLUS 600 mg effervescent tablets Acetylcysteine This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for
More informationPackage leaflet: Information for the patient. Xemacort 20 mg/g + 1 mg/g cream (fusidic acid and betamethasone)
PACKAGE LEAFLET Package leaflet: Information for the patient Xemacort 20 mg/g + 1 mg/g cream (fusidic acid and betamethasone) Read all of this leaflet carefully before you start using this medicine because
More informationPATIENT INFORMATION LEAFLET DYNARB RANGE
SCHEDULING STATUS: S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: DYNARB 75 mg tablets DYNARB 150 mg tablets DYNARB 300 mg tablets Read all of this leaflet carefully before you start taking DYNARB.
More informationPATIENT INFORMATION LEAFLET. Calcichew* 500 mg Chewable Tablets calcium carbonate
PATIENT INFORMATION LEAFLET Calcichew* 500 mg Chewable Tablets calcium carbonate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
More informationPatient Information Leaflet
Patient Information Leaflet Ibuprofen 5% w/w Gel Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you have any further questions
More informationREDERGIN 1.5 mg tablets; 4.5 mg tablets; 1 mg/ml oral solution
PACKAGE LEAFLET: INFORMATION FOR THE USER REDERGIN 1.5 mg tablets; 4.5 mg tablets; 1 mg/ml oral solution ERGOLOID MESYLATE This leaflet is a copy of the Summary of Product Characteristics and Patient Information
More informationPHARMACY ACTION COLD & FLU DAY & NIGHT paracetamol, pseudoephedrine hydrochloride, chlorphenamine maleate
CONSUMER MEDICINE INFORMATION PHARMACY ACTION COLD & FLU DAY & NIGHT paracetamol, pseudoephedrine hydrochloride, chlorphenamine maleate What is in this leaflet This leaflet answers some common questions
More informationPATIENT INFORMATION LEAFLET AMLOC RANGE
SCHEDULING STATUS: S3 PROPRIETARY NAME AND DOSAGE FORM: AMLOC 5 mg tablets AMLOC 10 mg tablet Read all of this leaflet carefully before you start taking AMLOC. Keep this leaflet. You may need to read it
More informationGlucophage XR is contra-indicated during breast-feeding.
Name GLUCOPHAGE XR 1000 mg Prolonged release tablets Active ingredient Metformin hydrochloride Composition Each Glucophage XR 1000 mg prolonged release tablet contains as active ingredient 1000 mg metformin
More informationPatient Information MICARDIS HCT (my-car-dis HCT) (telmisartan and hydrochlorothiazide) Tablets
Patient Information MICARDIS HCT (my-car-dis HCT) (telmisartan and hydrochlorothiazide) Tablets Read this Patient Information before you start taking MICARDIS HCT tablets and each time you get a refill.
More informationDESCRIPTION Locacorten-Vioform ear drops are a practically odourless clear, yellowish to brownish-yellow solution. Excipients: Macrogol 300
PRODUCT INFORMATION LOCACORTEN -VIOFORM Ear Drops NAME OF THE MEDICINE Flumethasone pivalate Chemical formula: C 27 H 36 F 2 O 6 (6α, 9-Difluouro-11β,17,21-trihydroxy-16α-methyl-pregna- 1,4-diene-3,20-dione
More informationCa-C 1000 Calvive 1000 mg mg mg effervescent tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Ca-C 1000 Calvive 1000 mg + 327 mg + 1000 mg effervescent tablets CALCIUM LACTATE GLUCONATE, CALCIUM CARBONATE, ASCORBIC ACID (VITAMIN C) This leaflet is a copy
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER RENNIE DUAL ACTION TABLETS. Calcium carbonate, Magnesium carbonate, Alginic acid Chewable tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER RENNIE DUAL ACTION TABLETS Calcium carbonate, Magnesium carbonate, Alginic acid Chewable tablets Read all of this leaflet carefully because it contains important
More informationPackage leaflet: Information for the user. Floxapen 250 mg & 500 mg Capsules. Flucloxacillin
Package leaflet: Information for the user Floxapen 250 mg & 500 mg Capsules Flucloxacillin Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationNormal Immunoglobulin (Human) 16%, solution for subcutaneous administration.
Normal Immunoglobulin (Human) 16%, solution for subcutaneous administration. Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about. It does not contain
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION BAVENCIO (buh-ven-see-oh) Avelumab for Injection Solution for Intravenous Infusion, 20 mg/ml Professed Standard Antineoplastic
More informationAPOHEALTH Diarrhoea Relief PLUS
APOHEALTH Diarrhoea Relief PLUS Chewable Tablets Contains the active ingredient Loperamide hydrochloride and Simethicone Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Neomycin Sulphate, Polymyxin B Sulfate and Bacitracin Zinc Powder
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory NEOSPORIN ANTIBIOTIC POWDER Neomycin Sulphate, Polymyxin B Sulfate and Bacitracin Zinc Powder QUALITATIVE AND QUANTITATIVE
More informationSensipar Cinacalcet hydrochloride
Sensipar Cinacalcet hydrochloride Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Sensipar. It does not contain all the available information. It
More informationPackage leaflet: Information for the patient. / / 30 mg/5 ml syrup. Ambroxol hydrochloride
Package leaflet: Information for the patient / / 30 mg/5 ml syrup Ambroxol hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: Read this entire leaflet carefully before you start taking DYNAFLOC.
SCHEDULING STATUS: S4 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: DYNAFLOC 250 (tablets) DYNAFLOC 500 (tablets) DYNAFLOC 750 (tablets) Read this entire leaflet carefully before you start taking
More informationPackage leaflet: Information for the user. <product name> 3 mg/ml eye drops, solution. Ofloxacin
Package leaflet: Information for the user 3 mg/ml eye drops, solution Ofloxacin Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
More informationHydrocortisyl Skin Cream 1% Hydrocortisone
PACKAGE LEAFLET: INFORMATION FOR THE USER Hydrocortisyl Skin Cream 1% Hydrocortisone Is this leaflet hard to see or read? Phone 01403 5600 for help Read all of this leaflet carefully before you start using
More informationPATIENT INFORMATION LEAFLET POLLENTYME S AND TABS
SCHEDULING STATUS: S1 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: POLLENTYME TABLETS (tablets) POLLENTYME S (syrup) Read all of this leaflet carefully because it contains important information
More informationMETHYLDOPA 250 mg Film-coated Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER METHYLDOPA 250 mg Film-coated Tablets METHYLDOPA This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationMEDICATION GUIDE SUTENT
MEDICATION GUIDE SUTENT (su TENT) (sunitinib malate) capsules Read the Medication Guide that comes with SUTENT before you start taking it and each time you get a refill. There may be new information. This
More informationPackage leaflet: Information for the user. Tianeptine 12.5 mg Film Coated Tablets (Tianeptine Sodium)
Package leaflet: Information for the user Tianeptine 12.5 mg Film Coated Tablets (Tianeptine Sodium) Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationFAVISTAN 20 mg, tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER FAVISTAN 20 mg, tablets TIAMAZOL This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More information1. What Solpadol is and what it is used for
PATIENT INFORMATION LEAFLET SOLPADOL 30mg/500mg CAPLETS Codeine Phosphate and Paracetamol Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read
More informationAll medicines have risks and benefits. Your doctor has weighed the risks of you taking Triprim against the benefits he or she expects it will have.
Triprim Tablets Trimethoprim Tablets Consumer Medicine Information What is in this leaflet? The leaflet answers some common questions about Triprim tablets. It does not contain all the available information
More informationPRESCRIBING INFORMATION
PRESCRIBING INFORMATION Bacitracin USP (Bacitracin for Injection USP) For Topical or Intramuscular Use in Solution 50 000 IU Sterile Powder Pfizer Canada Inc Date of Preparation: 17,300 Trans-Canada Highway
More informationFlavamed Forte 30 mg/5 ml, oral solution
PACKAGE LEAFLET: INFORMATION FOR THE USER Flavamed Forte 30 mg/5 ml, oral solution AMBROXOL HYDROCHLORIDE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen
PACKAGE LEAFLET: INFORMATION FOR THE USER EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS Ibuprofen Read all of this leaflet carefully before you start taking Easofen Max Strength Tablets because it contains
More informationBefore you are given Privigen
Normal immunoglobulin (Human) 10% (100 g/l), intravenous injection. Consumer Medicine Information What is in this leaflet This leaflet contains answers to some common questions about. It does not contain
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Xylonase 0.1% w/v Nasal Spray, Solution Xylometazoline hydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE USER Xylonase 0.1% w/v Nasal Spray, Solution Xylometazoline hydrochloride Read all of this leaflet carefully before you start using this medicine because it contains
More information2. What you need to know before you take DDAVP/Desmopressin Tablets
Package Leaflet: Information for the user DDAVP /Desmopressin 0.1mg Tablets Desmopressin Acetate Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPATIENT INFORMATION LEAFLET TEXAMER
SCHEDULING STATUS: S2 PROPRIETARY NAME AND DOSAGE FORM: film-coated tablets Read all of this leaflet carefully because it contains important information for you. is available without a doctor s prescription,
More informationPOLLENTYME S and Tabs Pharma Dynamics (Pty) Ltd Version: July 2017 (G1639) Word copy of G1639 PATIENT INFORMATION LEAFLET FOR POLLENTYME S AND TABS
PROPOSED FINAL PATIENT INFORMATION LEAFLET FOR POLLENTYME TABLETS & POLLENTYME S PATIENT INFORMATION LEAFLET SCHEDULING STATUS: S1 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: POLLENTYME TABLETS
More informationPACKAGE LEAFLET: INFORMATION FOR THE PATIENT
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Kopen Sugar Free 125mg/5ml and 250mg/5ml Powder for Oral Solution Phenoxymethylpenicillin Read all of this leaflet carefully before you start taking this medicine
More informationDuro-Tuss Dry Cough Liquid plus Nasal Decongestant Pholcodine (fol-co-dean); Pseudoephedrine hydrochloride (sue-doe-eff-eh-drine hydro-klor-ide)
Duro-Tuss Dry Cough Liquid plus Nasal Decongestant Pholcodine (fol-co-dean); Pseudoephedrine hydrochloride (sue-doe-eff-eh-drine hydro-klor-ide) Consumer Medicine Information What is in this leaflet This
More informationPART III: PATIENT MEDICATION INFORMATION. CLINDAMYCINE-150 Pr. CLINDAMYCINE-300 (Clindamycin Hydrochloride Capsules USP) Clindamycin 150 mg and 300 mg
PART III: PATIENT MEDICATION INFORMATION Pr CLINDAMYCINE-150 Pr CLINDAMYCINE-300 (Clindamycin Hydrochloride Capsules USP) Clindamycin 150 mg and 300 mg Read this carefully before you start taking CLINDAMYCINE
More informationPATIENT INFORMATION LEAFLET CARVETREND RANGE
SCHEDULING STATUS: S3 PATIENT INFORMATION LEAFLET PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: CARVETREND 6,25 mg tablet. CARVETREND 12,5 mg tablet. CARVETREND 25 mg tablet. Please read this leaflet
More informationNEOFEN 60 mg suppository
PACKAGE LEAFLET: INFORMATION FOR THE USER NEOFEN 60 mg suppository IBUPROFEN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationPATIENT INFORMATION LEAFLET Cyclophosphamide 50 mg Tablets Cyclophosphamide monohydrate
PATIENT INFORMATION LEAFLET Cyclophosphamide 50 mg Tablets Cyclophosphamide monohydrate Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read
More informationThyroid Gland. Patient Information
Thyroid Gland Patient Information Contact details for Endocrine and Thyroid Clinics Hawke s Bay Fallen Soldiers Memorial Hospital Villa 16 Phone: 06 8788109 ext 5891 Text: 0274 102 559 Email: endoclinic@hbdhb.govt.nz
More informationSodium Chloride 0.9% w/v Intravenous Infusion BP Solution for Infusion Sodium chloride
Package leaflet: Information for the user Sodium Chloride 0.9% w/v Intravenous Infusion BP Solution for Infusion Sodium chloride Read all of this leaflet carefully before using this medicine because it
More informationPRODUCT MONOGRAPH. Pr KYTRIL. granisetron hydrochloride tablets. 1 mg granisetron as hydrochloride. Manufacture Standard
PRODUCT MONOGRAPH Pr KYTRIL granisetron hydrochloride tablets 1 mg granisetron as hydrochloride Manufacture Standard Antiemetic (5-HT 3 receptor antagonist) Hoffmann-La Roche Limited Date of Revision:
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Emerade 150 micrograms solution for injection in pre-filled pen Emerade 300 micrograms solution for injection in pre-filled pen Emerade 500 micrograms solution
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Kaliumjodide G.L. 65 mg tabletten Potassium iodide
PACKAGE LEAFLET: INFORMATION FOR THE USER Kaliumjodide G.L. 65 mg tabletten Potassium iodide Read all of this leaflet carefully because it contains important information for you. This medicine is available
More informationIrbenida H 150mg/12,5mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Irbenida H 150mg/12,5mg film-coated tablets IRBESARTAN/HYDROCHLOROTHIAZIDE This leaflet is a copy of the Summary of Product Characteristics and Patient Information
More informationDulcolax 5 mg, film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Dulcolax 5 mg, film-coated tablets BISACODYL This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which
More informationConsumer Medicine Information PIMAFUCORT
Consumer Medicine Information PIMAFUCORT 1% Hydrocortisone, 1% Natamycin and 0.35% Neomycin Cream and Ointment What is in this leaflet This leaflet answers some common questions about Pimafucort Cream
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la]
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr NUCALA [new-ka la] mepolizumab lyophilized powder for subcutaneous injection Read this carefully before you start
More informationPATIENT INFORMATION LEAFLET FOR TEXA 10 mg TABLETS AND TEXA SYRUP PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM:
SCHEDULING STATUS: S2 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: TEXA 10 mg (tablets) TEXA SYRUP (syrup) Read this entire leaflet carefully before you start taking TEXA. Keep this leaflet. You
More informationLovastatin tablets 20 and 40 mg PACKAGE LEAFLET
PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER Lovastatin Mylan 20 mg Tablets Lovastatin Mylan 40 mg Tablets lovastatin Read all of this leaflet carefully before you start taking this medicine.
More informationMycamine Micafungin (as sodium)
Mycamine Micafungin (as sodium) Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Mycamine. It does not contain all the available information. It does
More informationPackage leaflet: Information for the patient. Clarithromycin Kern Pharma 500 film-coated tablets Clarithromycin
Package leaflet: Information for the patient Clarithromycin Kern Pharma 500 film-coated tablets Clarithromycin Read all of this leaflet carefully before you start taking this medicine because it contains
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Paracetamol 500 mg Effervescent Tablets Paracetamol
PACKAGE LEAFLET: INFORMATION FOR THE USER Paracetamol 500 mg Effervescent Tablets Paracetamol Read all of this leaflet carefully because it contains important information for you. This medicine is available
More informationPackage leaflet: Information for the user. Novastan 100 mg/ml concentrate for solution for infusion. argatroban monohydrate
Package leaflet: Information for the user 100 mg/ml concentrate for solution for infusion argatroban monohydrate Read all of this leaflet carefully before you start using this medicine because it contains
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. ANESDERM 25 mg/g + 25 mg/g Cream Lidocaine, Prilocaine
PACKAGE LEAFLET: INFORMATION FOR THE USER ANESDERM 25 mg/g + 25 mg/g Cream Lidocaine, Prilocaine Read all of this leaflet carefully before you start using this medicine because it contains important information
More information